Baseline characteristics of the Mexican population are available at <http://ensanut.insp.mx/>. The final dataset after running our model is available at the open science framework, [osf.io/5j4va](http://osf.io/5j4va) (doi: [10.17605/OSF.IO/5J4VA](https://doi.org/10.17605/OSF.IO/5J4VA)). The mathematical model used to estimate the impact on body weight is freely available in the github within an R package named \"bw\" in <https://github.com/INSP-RH/bw>.

Introduction {#sec007}
============

High consumption of ultra-processed food and beverages is associated with increased caloric intake and weight gain \[[@pmed.1003221.ref001],[@pmed.1003221.ref002]\]. Governments in many countries are establishing interventions to improve consumers' choices. In 2014, Mexico implemented a tax on sugar-sweetened beverages (SSBs) and nonessential highly caloric food, to discourage their consumption. The SSB tax was estimated to prevent 240 thousand cases of obesity and save US\$4 on healthcare costs for every dollar spent in its implementation \[[@pmed.1003221.ref003]\]. In October 2019, Mexico approved a new front of package labeling for nonalcoholic beverages and packaged food, under the law NOM-051 \[[@pmed.1003221.ref004]\]. In January 2020, after a period of discussion with all interested stakeholders, the rules and specific terms of the law were approved by the regulatory committee, with minor changes \[[@pmed.1003221.ref005]\]. The law includes all prepackaged food and beverages that add free sugars, fats (vegetable or animal), partially hydrogenated fats, or sodium (ingredient or additive) during the elaboration process. The law establishes a simple warning label with "excess of" calories, saturated fats, sodium, sugars, and trans fats ([Fig 1](#pmed.1003221.g001){ref-type="fig"}). It will also include an additional legend in capital letters \"contains sweeteners, not recommended in children\" or "contains caffeine, avoid in children." The Mexican law based the additives limits on the recommendation of the Pan American Health Organization (PAHO) \[[@pmed.1003221.ref004],[@pmed.1003221.ref006]\].

![Illustration of the warning labels proposed in Mexico under the NOM-051 \[[@pmed.1003221.ref004]\].](pmed.1003221.g001){#pmed.1003221.g001}

Warning labels have been proposed as a population-wide intervention to reduce the consumption of nonessential highly caloric food and beverages. Experimental studies have found that warning labels reduce the intention to purchase SSBs and snacks \[[@pmed.1003221.ref007]--[@pmed.1003221.ref012]\]. Using different designs of warning labels, the estimated reduction of calories ranged from 11.9% to 23.3% for beverages and from 5.5% to 11.7% for snacks \[[@pmed.1003221.ref010]--[@pmed.1003221.ref012]\]. A recent modeling study in the United States estimated that warning labels could reduce 25.3 kcal/day from SSBs, which was translated into a 3.1 percentage points (pp) reduction in the obesity prevalence \[[@pmed.1003221.ref013]\]. These studies suggest that warning labels on food and beverages could be an effective intervention to improve the quality of diet and to reduce calories and obesity prevalence.

Considering that the consumption of processed food and beverages in Mexico is amongst the highest worldwide \[[@pmed.1003221.ref002]\], we aimed to estimate the expected reduction in obesity prevalence and obesity costs in Mexico by introducing warning labels, over 5 years among adults under 60 years of age.

Methods {#sec008}
=======

We used a simulation model to estimate the future impact on obesity and obesity costs that could be reduced by modifying the NOM-051 to introduce warning labels to packaged products in Mexico. We first estimated the impact on reduction of calories, body mass index (BMI), and obesity prevalence and then estimated the direct and indirect costs that could be reduced ([Fig 2](#pmed.1003221.g002){ref-type="fig"}). Each step of the simulation strategy was detailed in the next subsections.

![Schematic illustration of the simulation strategy.\
Sources of information: ^1^Acton and colleagues, 2019; ^2^Hall and colleagues, 2011; ^3^ENSANUT 2016; ^4^Population projections from CONAPO \[[@pmed.1003221.ref010],[@pmed.1003221.ref014]--[@pmed.1003221.ref016]\]. CONAPO, Consejo Nacional de Población; SFFQ, semiquantitative food frequency questionnaire; SSB, sugar-sweetened beverage.](pmed.1003221.g002){#pmed.1003221.g002}

Baseline intake of beverages and snacks and BMI {#sec009}
-----------------------------------------------

Baseline intake of beverages and snacks, and anthropometric data were collected using the 2016 National Health and Nutrition Survey (ENSANUT, from its Spanish acronym) with 6,511 individuals aged 20--59 years. The ENSANUT is a probabilistic multistage stratified cluster survey representative at national, regional, and rural/urban levels \[[@pmed.1003221.ref015]\]. Within ENSANUT, we used the semiquantitative food frequency questionnaire (SFFQ) to estimate baseline intake of beverages and snacks. The SFFQ in 2016 was collected in all adults sampled for the ENSANUT up to 60 years old. It collects the consumption of 140 items over a week, including a variety of beverages and snacks that could have a warning label. Data include the number of days, times per day, serving size, and the number of times food was consumed during the 7 days prior to the interview. With the nutritional table, the quantity/day of beverages and snacks consumed was converted in daily energy intake for each subject (kcal/day/person), following standard procedures. The SFFQ was previously validated in Mexican adolescents and adults \[[@pmed.1003221.ref017]\]. We selected beverages and snacks according to Acton and colleagues, 2019. The specific items selected in this study are included in Table A ([S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}), and a detailed description is included in Section 2 ([S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}).

The SFFQ was merged to anthropometric data with BMI, height, and weight. The resulting dataset presented 315 pregnant and lactating women, 137 individuals with missing data for weight or height, nine individuals with implausible values of BMI (≥60 kg/m^2^), one individual with an extreme value of SSBs intake (\>16 servings/day \[[@pmed.1003221.ref010]\]), and one individual with missing data on the primary sampling unit. All these individuals were excluded from the analysis, resulting in a final sample with 6,049 adults aged 20--59 years that, once survey weights were applied, represented 48,289,840 individuals in the adult population in Mexico.

Reduction in energy intake from beverages and snacks {#sec010}
----------------------------------------------------

To estimate the expected impact of the warning labels on calories, we used an experimental marketplace study from Acton and colleagues using the "high in" warning label from Canada \[[@pmed.1003221.ref010]\]. This study evaluated the effect of "high in" labels on purchases for beverages and snacks separately and estimated the reduction on energy and nutrients (sodium, saturated fats, and sugar), including individuals over 13 years and older \[[@pmed.1003221.ref010]\]. We considered the reduction by 10.5% in beverages and by 3.0% in snacks, specifically for adults. The stratified results of Acton and colleagues by adults and adolescents are presented in Section 2.1 and Table E in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}. This caloric change was observed between the experimental and control groups, and considers substitutions for other beverages or snacks. We considered a sodium reduction of 7.6% and 8.3% for beverages and snacks, respectively, for adults from Acton and colleagues as an input to the hall's model to estimate extracellular liquid for each individual \[[@pmed.1003221.ref010]\].

In our study, we used the caloric effect, which includes the caloric reductions by specific labels, but other effects of saturated fats, sugars, and sodium are not considered. We assumed that the caloric effect using the Canadian warning labels would be similar to the Mexican warning labels, and that the reduction would occur at the beginning of the first year of implementation, remaining constant over time. Assumptions and source of information are described in Section 7 in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}, and the parameters used are described in [S1 Parameters](#pmed.1003221.s003){ref-type="supplementary-material"}.

Reduction in body weight, BMI, and obesity prevalence {#sec011}
-----------------------------------------------------

We estimated the expected impact on BMI attributable to warning label using a dynamic weight change model for adults, proposed by Hall and colleagues \[[@pmed.1003221.ref014]\]. The model estimates the change in body weight of each individual at time *t*, considering changes in extracellular fluid, glycogen, and fat and lean tissues triggered by the change in consumption of food and beverages with the warning labels, maintaining the physical activity constant. We ran the model for each year and up to five years to obtain the complete effect of caloric change in weight changes. In Mexico, this model was previously used in adults to estimate the expected impact of SSB tax and reformulation to reduce sugar content \[[@pmed.1003221.ref017],[@pmed.1003221.ref018]\]. The model structure is described in [S1 Parameters](#pmed.1003221.s003){ref-type="supplementary-material"} and a full description of the model can be found elsewhere \[[@pmed.1003221.ref014]\].

Reduction in cases with obesity {#sec012}
-------------------------------

After estimating changes in obesity prevalence, we translated these changes in cases averted over 5 years. For that purpose, we used population projections from the Consejo Nacional de Población (CONAPO) (in English, National Population Council), for adults 20--59 years old, from 2019 to 2023 \[[@pmed.1003221.ref016]\]. To estimate total cases of obesity over the simulated period, we multiplied the obesity prevalence estimated using ENSANUT 2018 for adults aged 20--59 (37.8%) and assumed a steady state for the obesity prevalence (i.e., prevalence does not change for any other reason but the warning label intervention). By multiplying the prevalence change by the estimated number of adults with obesity in Mexico, we estimated the cases of obesity that could be averted in the period 2019--2023.

### Sensitivity analysis {#sec013}

We conducted a sensitivity analysis to estimate the uncertainty range around the impact of warning labels in obesity cases. For beverages, we estimated three potential alternative scenarios. The first is based on observed reductions in an observational study in Chile; it assumes a 7.5% reduction in caloric intake from beverages after the implementation of "high in" labels and considers substitution for not "high in" beverages \[[@pmed.1003221.ref019]\]. The second and third scenarios are based on a stratified estimation from the same observational study in Chile, having a 27.5% decrease in "high in" and a 10.8% increase in "not high in" beverages \[[@pmed.1003221.ref019]\]. The second scenario categorizes \"high in\" or \"not high in\" beverages following the thresholds defined by the Chilean law, while the third scenario follows the thresholds proposed in the Mexican law. The limits thresholds proposed by Chile and Mexico are included in Table F and Table I in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}. For snacks, we used an experimental study from Uruguay, with 199 subjects from a university in Montevideo, which estimated an 11.68% caloric reduction and a 50.17% sodium reduction after the implementation of warning labels \[[@pmed.1003221.ref011]\]. More information on how beverages and snacks were selected can be found in Tables A and B in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}. More information on model parameters are included in [S1 Parameters](#pmed.1003221.s003){ref-type="supplementary-material"}.

Reduction in healthcare costs {#sec014}
-----------------------------

Obesity costs were obtained over 5 years after implementing the warning labels. For that, we used the financial report of the impact of overweight and obesity in Mexico 1999--2023 generated by the Health Ministry \[[@pmed.1003221.ref020]\]. Direct costs use the health system perspective, in which out-of-pocket expenses are not included. Indirect costs use the individual perspective, including premature death, absenteeism, and caregiver expenses from the individual perspective and pension allowance for work incapacity and disability from a social security perspective. As obesity costs in the report were obtained for the total population, we limited the obesity costs to the target population (20--59 years). More information about the source of data and a detailed description of cost estimations is included in Section 5 in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}.

We projected the estimated obesity costs in 2014 to the year 2019 using the price deflator based on the National Consumer Price Index of the Instituto Nacional de Estadística y Geografía (INEGI) (in English, the National Institute of Statistics and Geography) \[[@pmed.1003221.ref021]\] and discounted 3% yearly to estimate the costs over the next 4 years, following standard procedures in a cost-effectiveness analysis \[[@pmed.1003221.ref022]\]. Finally, we multiplied the absolute reduction in obesity prevalence by the obesity costs during the 5 years to estimate the total direct (healthcare) costs and indirect costs (premature deaths, work absenteeism, and others) that could be reduced among adults 20 to 59 years old. Costs in Mexican pesos (MXP) were converted to American dollars using the 2019 average exchange rate (1 MXP = 0.05190017 US\$) \[[@pmed.1003221.ref023]\]. A detailed description of cost estimations is included in Section 5 in [S1 Appendix](#pmed.1003221.s002){ref-type="supplementary-material"}. This study is reported as per the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline ([S1 Checklist](#pmed.1003221.s001){ref-type="supplementary-material"}).

Results {#sec015}
=======

[Table 1](#pmed.1003221.t001){ref-type="table"} presents the baseline intake of beverages and snacks among Mexican adults in 2016. We estimated a baseline intake of 220.9 kcal/day from beverages and 453.1 kcal/day from snacks, which together account for 31.1% of the total energy intake. The expected caloric change after the warning labeling was estimated to be −36.8 kcal/day (−23.2 kcal/day from beverages and −13.6 kcal/day from snacks).

10.1371/journal.pmed.1003221.t001

###### Baseline intake of beverages and snacks and its expected change in calories and sodium attributable to warning labels among adults 20--59 years old.

![](pmed.1003221.t001){#pmed.1003221.t001g}

  Food category   Baseline energy intake (kcal/day/person, CI 95%)   Baseline intake as a percentage of total energy intake (%)   Expected change in energy intake after the labeling (kcal/day/person, CI 95%)
  --------------- -------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------
  Beverages       220.9 (208.6 to 233.2)                             9.9                                                          −23.2 (−24.5 to −21.9)
  Snacks          453.1 (435.5 to 470.7)                             21.2                                                         −13.6 (−14.1 to −13.1)
  Total           674.0 (650.4 to 697.6)                             31.1                                                         −36.8 (−38.3 to −35.3)

[Table 2](#pmed.1003221.t002){ref-type="table"} presents the impact of warning labels in Mexico. Body weight is expected to decrease by 1.68 kg (1.05 kg from beverages and 0.63 kg from snacks) and BMI by 0.65 kg/m^2^. This reduction would imply a 4.98 pp reduction in obesity over five years, representing 1.3 million cases of obesity among adults under 60 years.

10.1371/journal.pmed.1003221.t002

###### Weight, BMI, obesity, and prevalence change attributable to warning labels over 5 years among adults 20--59 years old.

![](pmed.1003221.t002){#pmed.1003221.t002g}

  Health outputs                       Baseline, CI 95%         Change over 5 years for beverages, CI 95%   Change over 5 years for snacks, CI 95%   Total change over 5 years, CI 95%
  ------------------------------------ ------------------------ ------------------------------------------- ---------------------------------------- -----------------------------------
  Body weight (kg)                     72.38 (71.60 to 73.16)   −1.05 (−1.11 to −1.00)                      −0.63 (−0.65 to −0.60)                   −1.68 (−1.75 to −1.61)
  BMI (kg/m^2^)                        28.34 (28.08 to 28.60)   −0.41 (−0.43 to −0.38)                      −0.25 (−0.26 to −0.24)                   −0.65 (−0.68 to −0.63)
  Obesity prevalence (pp)              33.81 (31.54 to 36.07)   −2.92 (−3.67 to −2.16)                      −1.83 (−2.45 to −1.22)                   −4.98 (−6.03 to −3.93)
  Cases of obesity (thousand people)   26,174                   764                                         479                                      1,303

Abbreviations: BMI, body mass index; pp, percentage point

[Fig 3](#pmed.1003221.g003){ref-type="fig"} presents the impact of warning labels in Mexico in obesity prevalence over 5 years by age groups, sex, and socioeconomic status (SES) groups. Expected reductions in obesity, with respect to baseline, were larger among adults under 40 years (−17.2%) in comparison with individuals between 40--59 years (−12.2%). Also, males presented larger obesity reductions (−16.2%) in comparison to females (−13.8%). Middle and high SES (−15.1% and 15.5%) presented larger obesity reductions in comparison with low SES (−12.6%). The specific absolute and relative yearly changes can be found in Table T in [S1 Appendix](#pmed.1003221.s003){ref-type="supplementary-material"}.

![Percent change (%) of obesity prevalence over 5 years by age group, sex, and SES. SES, socioeconomic status.](pmed.1003221.g003){#pmed.1003221.g003}

[Fig 4](#pmed.1003221.g004){ref-type="fig"} presents the range of potential reduction in obesity cases varying the parameter effect of warning labels on beverages and snacks. We found that warning labels could reduce from 764 thousand (main scenario) to 1.07 million of people with obesity over 5 years through reducing beverages intake. In addition, warning labels could reduce from 479 thousand (main scenario) to 1.73 million people with obesity through reducing snacks intake.

![Potential impact on obesity cases reduced using different scenarios, stratified by beverages and snacks.\
Main scenario: Effect estimate (10.5% and 3.0% caloric reduction for beverages and snacks, respectively) based on a Canadian experimental study. Scenario 1: Effect estimate (7.5% caloric reduction) based on Chilean observational study. Scenario 2: Effect estimate (caloric reduction by 27.5% in "high in" beverages and caloric increase by 10.8% in not "high in" beverages) based on Chilean observational study and adding the Chilean limits for the first stage of the law (Table F in [S1 Appendix](#pmed.1003221.s003){ref-type="supplementary-material"}). Scenario 3: Effect estimate (caloric reduction by 27.5% in "high in" beverages and caloric increase by 10.8% in not "high in" beverages) based on Chilean observational study and adding the Mexican limits (Table H in [S1 Appendix](#pmed.1003221.s003){ref-type="supplementary-material"}). Scenario 1 snacks: Effect estimate (11.68% caloric reduction for snacks) based on Uruguayan study.](pmed.1003221.g004){#pmed.1003221.g004}

[Table 3](#pmed.1003221.t003){ref-type="table"} presents the direct and indirect costs that could be reduced over 5 years after implementing the warning labels in Mexico. Obesity costs for the adult population under 60 years of age was estimated to be US\$44.5 billion, from which 40% were indirect costs. With the warning labels, we estimated that 5 years after implementation, we would be able to potentially save US\$1.8 billion, including US\$742 million from indirect costs.

10.1371/journal.pmed.1003221.t003

###### Obesity costs prevented due to warning labels in Mexico after 5 years among adults 20--59 years old.

![](pmed.1003221.t003){#pmed.1003221.t003g}

  Cost outputs over 5 years                  Baseline costs   Change in costs
  ------------------------------------------ ---------------- -----------------
  Direct costs of obesity (million US\$)     26,591           −1,100
  Indirect costs of obesity (million US\$)   17,944           −742
  Total costs reduced (million US\$)         44,535           −1,842

All costs are from 2019.

Discussion {#sec016}
==========

We aimed to estimate the potential impact of warning labels in beverages and snacks in Mexico over the obesity prevalence and obesity-related costs. The warning labels were estimated to reduce 36.8 kcal/day, which could reduce 4.98 pp in the obesity prevalence among adults under 60 years (−14.7%, with respect to baseline). Converted to absolute numbers over 5 years, this strategy was estimated to reduce 1.3 million cases of obesity and save US\$1.8 billion in obesity costs.

Some countries have already implemented warning labels for foods and beverages, including Chile, Peru, and Uruguay \[[@pmed.1003221.ref024]\]. To our knowledge, none of these countries have estimated yet the observed impact of warning labels on obesity prevalence. A modeling study in 2019 estimated the future impact of warning labels in the US, considering only the effect on beverages \[[@pmed.1003221.ref013]\]. The warning labels modeled consisted of a rectangle with the text "WARNING: Beverages with added sugar contribute to tooth decay, diabetes, and obesity." To inform the expected changes in calories, the authors used as the main scenario the effect of warnings on willingness to pay or on purchasing beverages among adults (−12.7%), while we used an experimental study in Canada with "high in" labels (−10.5% for beverages). As a result, the estimated change in calories for beverages was higher in the US than in Mexico (25.3 kcal/day versus 23.2 kcal/day). Using a sample distribution for caloric compensation, the US study found a total caloric change of 31.2 kcal/day, while we included the caloric change from snacks, predicting a total caloric change of 36.8 kcal/day. The caloric change was translated into identical expected reductions in BMI but into larger reductions in obesity prevalence (3.1 pp versus 4.98 pp in our study). Differences could be due to the BMI distribution, with more people in Mexico being near the obesity cutoff. Another modeling study estimated the impact of traffic-light nutrition labels on solids among adult Australians \[[@pmed.1003221.ref025]\]. The authors estimated a caloric change of −36.7 kcal/day for males and −21.1 kcal/day for females, in comparison with −13.6 kcal/day observed in snacks in our study. Differences are explained by the expected caloric change after the implementation of warning labels for solids: −10% in the Australian study, based on three studies, compared to −3.0% used in our study \[[@pmed.1003221.ref026]--[@pmed.1003221.ref028]\]. Overall, we consider that our assumptions are conservative and based on the best available experimental evidence for warning labels.

To our knowledge, our study is the first to estimate the obesity costs that could be reduced by implementing the warning labels. We estimated that warning labels could save more than US\$1.8 billion in obesity costs, from which \$1.1 billion were direct and \$742 million were indirect costs. The "traffic-light" nutrition labeling was estimated to save around US\$367 million in obesity prevention \[[@pmed.1003221.ref025]\]. Our direct cost savings are nearly triple because we are also considering reductions in beverages. Other differences may be due to the following: (1) costs in the Australian study are based in 2003, whereas in our study, in 2019, (2) the Mexican adult population is over 5 times the Australian population, and (3) obesity prevalence is higher in Mexico than in Australia. While estimating the cost-effectiveness of the warning labels is beyond the scope of this article, considering that the cost estimated by the industry to implement the nutrition labeling Daily Nutrition Guidelines in Mexico was US\$312.6 million (cost translated to dollars in 2019) \[[@pmed.1003221.ref029]\], warning labels would save US\$5.9 for each dollar spent in implementing, being a cost-benefit intervention.

Our modelling study presents several limitations and several layers of uncertainty. To inform the caloric change after the warning label, we used an experimental study that employed a single red warning label and nutrition thresholds proposed by Health Canada. While we used the baseline caloric intake from Mexico, the effect size from Canada (−10.5% for beverages and −3% for snacks) could change in the Mexican population. The Mexican law has more restrictive limits than the proposed law in Canada (Section 2 in [S1 Appendix](#pmed.1003221.s003){ref-type="supplementary-material"}), which could result in more products having the warning label and a higher caloric reduction. As transporting the effect from Canada to Mexico is challenging, we varied the caloric reduction parameter using estimates from Chile (for beverages) and from Uruguay (for snacks). For beverages, we estimate an obesity case reduction ranging from 764,000 to 1,068,000, and for snacks ranging from 479,000 to 1,733,000 of obesity cases. We decided to keep the Canadian scenario as our main analysis because it is experimental and was the only source with effect size for both beverages and snacks. Also, the Canadian scenario produced the most conservative results. Our model relies on a steady-state assumption. Because it is an individual-level simulation model and a closed cohort, we could not integrate into our estimation process the increasing obesity trend that the Mexican adult population is still experiencing (in 2016, the obesity prevalence was 33.3% compared to 36.1% in 2018) \[[@pmed.1003221.ref030]\]. Lack of consideration for the increasing obesity trend would lead to an underestimation of the total number of obesity cases reduced, because the estimated reduction over time would be multiplied by fewer obesity cases.

Our model focuses on the estimation of the expected body weight change as result of a reduction in caloric intake associated with warning labels. However, warning labels could produce health benefits that we are not modeling. For instance, the warning label is expected to reduce 8.3% of sodium consumption from snacks, which should have a major impact on reducing blood pressure, cardiovascular diseases, hypertension, and overall mortality. Also, expected reductions in saturated fat or sugars (not considered in this analysis) would have an impact on diabetes or atherosclerosis that are not mediated through obesity; thus, other health benefits need to be independently assessed and considered. Our analysis is limited to the direct effect of warning labels on purchase intention and does not take into consideration the potential reformulation that could be induced by the threshold at which a label is implemented. Reformulation is a voluntary strategy that the industry has been employing to reduce sodium, saturated fats, and added sugars to avoid high taxes or warning labels. While Chile observed very small reductions in critical nutrients before the law came into effect (June 2016), to our knowledge, Chile has not yet evaluated the reformulation effect after implementing the warning labels \[[@pmed.1003221.ref031]\]. However, 29% and a 40% reductions in sugar content were observed on taxed beverages in the United Kingdom and South Africa, respectively \[[@pmed.1003221.ref032],[@pmed.1003221.ref033]\].

Other limitations regarding the nutrition assessment tool used (SFFQ from 2016) need to be mentioned. The SFFQ 2016 was collected from May to August 2016, during the summer months in Mexico, when beverage consumption increases in comparison to winter, which could lead to overestimate the impact of the warning labels, compared to the annual SSB consumption. However, self-reported nutrition tools such as the SFFQ tend to underestimate the consumption of highly caloric food and beverages, and the underestimation is usually higher among people with higher BMI. If consumption is underestimated, our predictions would be conservative. The SFFQ over 7 days in comparison with 24-hour dietary recall may have larger measurement error due to recall bias. However, we decided to use the SFFQ in order to capture the usual intake by an individual and because the 24-hour dietary recall from ENSANUT 2016 had a smaller sample size (four times less). Finally, we are assuming that producers and supermarkets will comply 100% with the law. A previous study in Chile observed a high level of compliance from producers, with 32 out of 41 products implementing the warning labels; however, full compliance was not attained \[[@pmed.1003221.ref034]\].

Our study models the potential impact of warning labels, relaying in a large set of assumptions that could diverge from the real-life conditions of implementation. Thus, it will be important to conduct future studies to contrast our projections against observational data. Building upon the literature from SSBs, we propose for studies to analyze different end points, such as changes in sales, purchases, and consumption of labeled versus unlabeled products \[[@pmed.1003221.ref035],[@pmed.1003221.ref036]\]. It will also be important to analyze changes in body weight, incidence of chronic diseases, and biomarkers, although these studies will be difficult to conduct given that labels will be implemented at the same time in the whole nation. The uncertainty about the lag between the intervention and the expected effects, and the magnitude of the expected change (−1.68 kg, according to our estimates) could be difficult to detect even in large, well-conducted longitudinal studies.

The obesity epidemic is one of the biggest public health challenges for modern societies. A single intervention such as warning labels will not be the silver bullet to eradicate obesity. Structural interventions are needed to counter the increasing trends in body weight that have been observed in Mexico and other countries. Mexico has been at the forefront of implementation of structural interventions to curb the obesity epidemic, such as the tax to SSBs and nonessential high caloric food; the SSB tax was estimated to reduce on average 0.15 kg/m^2^ in the adult population \[[@pmed.1003221.ref018]\]. Another modeling study estimated that SSB tax could reduce 0.21 pp in obesity prevalence, while the warning label is expected to reduce 4.9 pp in adults below 60 years. Warning labels seem capable of reducing body weight through an independent mechanism, being likely additive to the impact of taxes; future analyses are needed to understand how taxes and warning labels interact to produce changes in consumption, so that any potential overlap or synergy can be considered when designing these interventions.

Warning labels on processed food and beverages are expected to effectively reduce obesity (−14.7%, with respect to baseline) and could save US\$1.8 billion in obesity costs. Latin American countries are following Chile, implementing warning labels to inform consumers, reduce market failures, and facilitate healthier dietary choices. While more efforts will be needed to curb the obesity epidemic in Mexico, it is clear that warning labels have the potential to benefit the Mexican population by preventing an important number of obesity cases and costs.
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Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by May 31 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

Abstract

Background-please provide further info about the law on warning labels-whether it is single or multi labels etc and which products require these warning labels

Methods and findings section needs more information about the model, assumptions/data used to create the model

Please clarify what data sources were used to estimate costs

Last sentence of the methods and findings section should include a limitation of the study design/methodology

Abstract Conclusions:

\* Please address the study implications without overreaching what can be concluded from the data; the phrase \"In this study, we observed \...\" may be useful.

\* Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

\* Please avoid vague statements such as \"these results have major implications for policy/clinical care\". Mention only specific implications substantiated by the results.

\* Please avoid assertions of primacy (\"We report for the first time\....\")

Author summary

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Please add a full stop after the references in square brackets

Introduction

Please can you provide brief details of the law on warning labels (as stated above). Please add details of which food/drinks are eligible

Please clarify in text if the law NOM-051 is the SSB taxation law that was implemented in 2014

Please provide a reference for "Considering that the consumption of industrialized food products in Mexico is amongst the highest worldwide"

Please rephrase "obesity costs that could be averted in the country by introducing warning labels, over 5 years among adults under 60 years of age" to more accurately reflect the aim of your work. It is also not clear whether obesity costs can be fully averted with warning labels, so I would avoid this type of language

Methods

Please include the citation for the study Acton et al when it is first mentioned on page 4

You may wish to comment why you used estimates from Canada- since the population is quite different as is the warning label

"Acton, et al., observed that adults experienced smaller caloric reductions (10.5% in beverages

and 3.0% in snacks) compared to adolescents (16.7% in beverages and 15.9 % in snacks) (data provided by the authors)" -- if this information is not published, please include this data as SI files or remove this information. Please note the methods section should only include the methodology of your study, so the middle paragraph on page 5 should be removed

Section 1.3 should be moved up in the methods section as it provides important information about the model used

Please state the Spanish name of the national population council and National Institute of Statistics and Geography, providing the English names in brackets along with acronyms for clarity

Please reconsider the repeated use of the phrase "costs averted" or "averted". There can be a reduction in cost but I am not sure these can be completely averted by the use of warning labels.

Please format the bibliography in Vancouver style

Please present and organize the Discussion as follows: a short, clear summary of the article\'s findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Please ensure that the study is reported according to the STROBE/CHEERS guideline, and include the completed checklists as Supporting Information. When completing the checklist, please use section and paragraph numbers, rather than page numbers. Please add the following statement, or similar, to the Methods: \"This study is reported as per the XXX guideline (S1 Checklist).\"

Comments from the reviewers:

Reviewer \#1: In this study, the authors attempt to estimate the expected change in the obesity prevalence and obesity costs that could be averted in Mexico by introducing warning labels, over 5 years among adults under 60 years of age.

Under Abstract (and throughout the manuscript):

\"Our estimate is based on experimental evidence derived from warning labels as proposed in Canada, which include a single label and less restrictive limits to sugar, sodium and saturated fats; however, the Mexican warning label law is much stricter and includes up to five warning labels per product, thus, our estimates are conservative.\"

The different labeling protocol does not necessarily make this analysis more conservative. There could be many factors at play which may have an impact on effectiveness of labeling.

\"Mexico is following Chile, Peru and Uruguay in implementing warning labels to processed foods, but other countries could benefit from this intervention.\"

Is it possible to use evidence gathered from Chile, Peru and Uruguay to estimate the effectiveness and impact of labeling in Mexico?

Under Methods:

\"All these individuals were excluded from the analysis, resulting in a final sample with 6,050 adults aged 20-59 years, representing 48,290,327 individuals. \"

Can the authors please clarify this sentence?

\"We assumed that the caloric effect using the Canadian warning labels would be similar to the Mexican warning labels, and that the reduction would occur at the beginning of the first year of implementation, remaining constant over time.\"

Is Canada similar to Mexico in terms of cultural attitudes towards snacking, as well as quantity and type of snacks consumed?

\"\...assumed steady state for the obesity prevalence (i.e., prevalence does not change for any other reason, but the warning label intervention).\"

Does this account for longitudinal trends of obesity seen in Mexico (i.e. is there an otherwise increasing prevalence in obesity)?

Under Results:

The tables are clear and easy to interpret.

Table 3 would benefit from being displayed as a graph or chart, with lines or columns representing changes over time for age group, sex and socioeconomic status groups.

The analysis and results would be far more robust and could be interpreted with more appropriate uncertainty if variability in assumptions and sensitivity analyses were accounted for in the simulated estimates.

Furthermore, the results of this additional assessment of uncertainty could then be included in Table 4.

Under Supplementary Information:

The S1 Appendix is a useful resource for the reader to better understand the model and underlying assumptions.

Reviewer \#2: Expected obesity reduction after implementing warning labels in Mexico: a modeling study

1\. This article models the potential impact of warning labels for beverages and snacks on obesity and obesity-related costs in Mexico. The topic is important, and the motivation is enhanced by the fact that such a policy recently has passed. The study is well-written and the methods and results are quite clear.

2\. The article does not use a checklist for completeness. If relevant, formally or informally, it would be good to reference a checklist such as CHEERS or an authoritative source for methods, such as the second panel report for cost-effectiveness analysis (Neumann et al.). Even though this is not a formal cost-effectiveness analysis, that report may be useful. It is referenced in this article just as authority for 3% discount rate, but the application may be more widespread.

3\. For example, current practice for such articles may require use of probabilistic or deterministic sensitivity analysis, which the article does not have. The article argues essentially that it has placed a bound on the plausible estimates, so any sensitivity to assumptions is in only one direction, but this cannot be determined with confidence. In the discussion, greater uncertainty should be acknowledged. In such articles, the output depends on uncertain in several layers of inputs.

4\. In particular, the article is especially highly reliant on the ability to apply an estimate from a labeling experiment in Canada (Acton) to nationwide impact in Mexico. The Acton study is sufficiently central that more features of methods and limitations should be briefly summarized in this article. Uncertainty bounds in the Acton estimates could be considered in sensitivity analysis in this article. It is not clear if calorie changes from that study can be maintained without modification nationwide for intake in Mexico. It should be noted that the Acton study appears to be largely a hypothetical experiment, with a randomly assigned purchase offering just partial realism for actual economic impact for respondents. If the Acton study uses only purchase as the outcome, rather than daily intake, then there may be compensation at other times of day, leading daily intake proportional effects to be smaller.

5\. Because the policy is actually being implemented, the article could discuss how future evidence from the field can be compared to these modeling estimates. In a scientific spirit, one could point out whether and how the estimates in this study can and should be corroborated.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003221.r003
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4 Jun 2020

Dear Dr. Barrientos-Gutierrez,

Thank you very much for re-submitting your manuscript \"Expected obesity reduction after implementing warning labels in Mexico: a modeling study\" (PMEDICINE-D-20-00367R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 11 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title- Please replace \"expected\" with \"predicting\" given it's a modelling study.

Please add a space in front of the square bracket for references throughout the submission

Line 118 'industrialised' -- I wonder if factory made or processed might be better

CHEERS checklist- please remove page and line numbers as these are likely to change. Please use paragraphs and sections instead

Abstract

Please define "pp" on first view

The limitations have not ben clearly laid out. It is not sufficient to say that the study findings need to be confirmed but please include limitations of your study design. For instance- the use of evidence from Canada applied to Mexico might have some limitations. Please do add these to the author summary as well

Line 95- I'm not sure about market failures. Could you please clarify and revise as needed

Line 352- I think there have been a few studies describing reformulation due to SSBs. I am not asking you to cite all the evidence here necessarily but it would be incorrect to say no studies have been published. Please let me know if I have misinterpreted this sentence

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please provide a complete list of model parameters, including clear and precise descriptions of \[the meaning of each parameter, together with the values or ranges for each, with justification or the primary source cited, and important caveats about the use of these values noted\]. Please discuss the scientific rationale for this choice of model structure and identify points where this choice could influence conclusions drawn. Please also describe the strength of the scientific basis underlying the key model assumptions.

Throughout, please clarify if the costs calculated are from the perspective of the health system or the individual.

Comments from Reviewers:

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003221.r004
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24 Jun 2020

Dear Dr. Barrientos-Gutierrez,

On behalf of my colleagues and the academic editor, Dr. Karine Clément, I am delighted to inform you that your manuscript entitled \"Predicting obesity reduction after implementing warning labels in Mexico: a modeling study\" (PMEDICINE-D-20-00367R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
